The Center for Drug Evaluation (CDE) has announced a new initiative aimed at enhancing the efficiency of resolving patent disputes during the review process for generic drug market filings. Patent holders, stakeholders, and generic drug applicants can now directly submit applications for setting a waiting period, as well as acceptance notices, judgments, decisions, or settlements, through the online platform at https://zldj.cde.org.cn, eliminating the need for traditional official document submissions.
For those who have previously submitted materials via official channels and are awaiting evaluation of their generic drugs, the CDE encourages resubmission on the designated website to facilitate tracking of processing progress and outcomes. This streamlined approach is expected to accelerate the review process and improve communication among involved parties.- Flcube.com
